GO:0008247 1-alkyl-2-acetylglycerophosphocholine esterase complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008247 describes the platelet-activating factor acetylhydrolase (PAF-AH) complex, an enzyme assembly that degrades the potent lipid mediator PAF.
• The complex is a heterotrimer composed of two catalytic alpha subunits (alpha1/alpha1, alpha2/alpha2, or alpha1/alpha2) and one non-catalytic beta subunit.
• PAF-AH activity modulates inflammation and vascular biology by removing the acetyl group from PAF, thereby inactivating it.
• The beta subunit is regulatory and shares homology with the LIS1 protein, which is critical for neuronal migration and dynein regulation.
• Mutations in the beta subunit (PAFAH1B1/LIS1) cause lissencephaly, a severe neurodevelopmental disorder, linking the complex to brain development.
• Studying this complex requires tools such as knockout, point-mutation, and tagged knock-in cell models to dissect subunit-specific functions.
Description
The 1-alkyl-2-acetylglycerophosphocholine esterase complex (GO:0008247), also known as the platelet-activating factor acetylhydrolase (PAF-AH) complex, is a multi-subunit enzyme that hydrolyzes the acetyl group from platelet-activating factor (PAF), a potent phospholipid mediator of inflammation and thrombosis. This complex is essential for regulating PAF signaling, and its dysfunction has been implicated in various pathological conditions, including cardiovascular diseases and neurodevelopmental disorders. Understanding the structure, assembly, and regulation of this complex is therefore of significant interest to researchers in lipid biology, inflammation, and neuroscience. The complex is composed of two catalytic alpha subunits and a non-catalytic beta subunit, with the beta subunit being homologous to the LIS1 protein, a key regulator of dynein-mediated transport. This dual role connects PAF metabolism to fundamental processes such as neuronal migration and intracellular trafficking. In this article, we provide a comprehensive overview of the GO:0008247 complex, covering its definition, composition, biological functions, associated genes, disease relevance, and modern research methodologies, including CRISPR-based models.
1-alkyl-2-acetylglycerophosphocholine esterase complex At A Glance
| GO ID | GO:0008247 |
|---|---|
| GO term | 1-alkyl-2-acetylglycerophosphocholine esterase complex |
| Ontology | cellular_component |
| Synonym | 2-acetyl-1-alkylglycerophosphocholine esterase complex; platelet-activating factor acetylhydrolase complex |
| Major function | Hydrolyzes platelet-activating factor (PAF) to lyso-PAF, thereby modulating PAF signaling. |
| Subunit composition | Two catalytic alpha subunits (alpha1/alpha1, alpha2/alpha2, or alpha1/alpha2) and one non-catalytic beta subunit. |
| Catalytic activity | Serine esterase activity; uses a catalytic triad. |
| Regulatory subunit | Beta subunit (PAFAH1B1/LIS1) is non-catalytic and regulates complex activity and localization. |
| Associated diseases | Lissencephaly (beta subunit mutations), cardiovascular disorders, inflammation. |
What Is GO:0008247?
The 1-alkyl-2-acetylglycerophosphocholine esterase complex is an enzyme assembly defined by the Gene Ontology as a complex composed of two catalytic alpha subunits that form a catalytic dimer (which can be an alpha1/alpha1 homodimer, an alpha2/alpha2 homodimer, or an alpha1/alpha2 heterodimer) and a non-catalytic, regulatory beta subunit. This complex modulates the action of platelet-activating factor (PAF) by catalyzing the hydrolysis of the acetyl group at the sn-2 position of PAF, converting it to the biologically inactive lyso-PAF.
Why Is 1-alkyl-2-acetylglycerophosphocholine esterase complex Important in Cell Biology?
The 1-alkyl-2-acetylglycerophosphocholine esterase complex is critically important because it controls the levels of platelet-activating factor (PAF), a phospholipid mediator with potent pro-inflammatory and pro-thrombotic activities. By degrading PAF, the complex prevents excessive inflammation and maintains vascular homeostasis. Dysregulation of PAF-AH activity has been linked to atherosclerosis, asthma, and sepsis. Moreover, the beta subunit of the complex is identical to LIS1, a protein essential for neuronal migration and dynein motor function; mutations in LIS1 cause lissencephaly, a severe brain developmental disorder. Thus, the complex sits at the intersection of lipid signaling and neurodevelopment, making it a subject of intense research.
• Regulates PAF levels, a key mediator of inflammation and thrombosis.
• Beta subunit (LIS1) is critical for dynein-mediated transport and neuronal migration.
• Mutations in the beta subunit cause lissencephaly, a neurodevelopmental disorder.
• PAF-AH activity is associated with cardiovascular diseases such as atherosclerosis.
• The complex is a potential therapeutic target for inflammatory conditions.
• Studying its assembly provides insights into heterotrimeric enzyme regulation.
• Links lipid metabolism to cytoskeletal dynamics via LIS1.
• Provides a model for understanding alpha/beta subunit interactions in enzyme complexes.
• Relevant to cancer biology through PAF's role in tumor progression.
• Enables research on PAF-related signaling pathways in various cell types.
What Happens During 1-alkyl-2-acetylglycerophosphocholine esterase complex?
Substrate Recognition and Binding
In simple terms: The complex grabs onto PAF, a lipid messenger, to get ready to break it down.
The catalytic alpha subunits of the PAF-AH complex recognize and bind platelet-activating factor (PAF), a phospholipid with an acetyl group at the sn-2 position. The binding involves hydrophobic interactions with the alkyl chain at the sn-1 position and electrostatic interactions with the phosphorylcholine headgroup. This positions the acetyl group near the catalytic triad for hydrolysis.
Catalytic Hydrolysis
In simple terms: The complex cuts the acetyl group off PAF, turning it into an inactive form.
The catalytic mechanism involves a serine esterase triad (Ser-His-Asp) in the alpha subunits. The serine residue attacks the carbonyl carbon of the acetyl group, forming an acyl-enzyme intermediate, which is then hydrolyzed by water to release acetate and lyso-PAF. This reaction inactivates PAF, terminating its signaling.
Regulation by the Beta Subunit
In simple terms: The beta subunit acts like a brake or switch, controlling how active the complex is.
The non-catalytic beta subunit (PAFAH1B1/LIS1) regulates the complex's activity and stability. It does not participate in catalysis but modulates substrate access and may influence subcellular localization. The beta subunit is also involved in dynein regulation, linking the complex to microtubule-based transport.
Assembly of the Heterotrimer
In simple terms: The pieces come together: two alpha subunits pair up, and one beta subunit joins them.
The complex assembles from two catalytic alpha subunits (which can be alpha1 or alpha2) that form a dimer, and one beta subunit. The alpha subunits share significant homology and can form homodimers or heterodimers, while the beta subunit associates with the dimer to form the active heterotrimer. The assembly is likely coordinated by chaperones, but details remain to be fully elucidated.
Key Genes Involved in GO:0008247 1-alkyl-2-acetylglycerophosphocholine esterase complex
The following genes encode the subunits and related proteins of the 1-alkyl-2-acetylglycerophosphocholine esterase complex, along with other proteins that interact with or regulate this complex.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PAFAH1B1 | Encodes the non-catalytic beta subunit (LIS1); regulates complex activity and dynein function | Mutations cause lissencephaly; key for neuronal migration studies |
| PAFAH1B2 | Encodes catalytic alpha2 subunit; forms homodimers or heterodimers with alpha1 | Isoform-specific functions in PAF metabolism |
| PAFAH1B3 | Encodes catalytic alpha1 subunit; forms homodimers or heterodimers with alpha2 | Isoform-specific functions in PAF metabolism |
| PLA2G7 | Encodes lipoprotein-associated phospholipase A2 (Lp-PLA2), a secreted PAF-AH | Cardiovascular disease biomarker; distinct from intracellular complex |
| DYNC1H1 | Dynein heavy chain; interacts with LIS1 for microtubule transport | Mutations cause neurodevelopmental disorders |
| NDE1 | Nuclear distribution protein; interacts with LIS1 in dynein pathway | Regulates neuronal migration |
| NDEL1 | NudE-like protein; partner of LIS1 in dynein regulation | Involved in cortical development |
| DCX | Doublecortin; microtubule-associated protein in migrating neurons | Mutations cause lissencephaly |
| VLDLR | Very low-density lipoprotein receptor; reelin pathway component | Associated with lissencephaly with cerebellar hypoplasia |
| RELN | Reelin; secreted protein guiding neuronal migration | Mutations cause lissencephaly |
| CDK5 | Cyclin-dependent kinase 5; phosphorylates NDEL1 | Regulates neuronal migration |
| LIS1 | Alias for PAFAH1B1; see above | See PAFAH1B1 |
| PAF | Platelet-activating factor; substrate of the complex | Key lipid mediator in inflammation |
| LPCAT | Lysophosphatidylcholine acyltransferase; may regenerate PAF | Balances PAF levels |
| PLA2G4A | Cytosolic phospholipase A2; produces PAF precursors | Inflammatory signaling |
| PTGS2 | Cyclooxygenase-2; inflammation-related enzyme | Cross-talk with PAF signaling |
| NFKB1 | NF-kB subunit; transcription factor in inflammation | Regulates inflammatory genes |
| MAPK1 | ERK2; kinase in signaling cascades | Downstream of PAF receptor |
How Is 1-alkyl-2-acetylglycerophosphocholine esterase complex Regulated?
The activity of the 1-alkyl-2-acetylglycerophosphocholine esterase complex is regulated at multiple levels. The beta subunit (LIS1) modulates the complex's catalytic activity and subcellular localization. Phosphorylation of LIS1 by CDK5 and other kinases affects its interaction with dynein and potentially the PAF-AH complex. Additionally, the expression of the alpha and beta subunits is developmentally regulated, with high levels in the brain. Inflammatory stimuli can induce the expression of secreted PAF-AH (Lp-PLA2), but the intracellular complex is more constitutively expressed. The complex may also be regulated by availability of substrate PAF, which is produced by phospholipase A2 and acetyltransferase activities.
1-alkyl-2-acetylglycerophosphocholine esterase complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PAFAH1B1 | Lissencephaly, neuronal migration disorders | Knockout mouse, patient-derived iPSC neurons |
| PLA2G7 | Atherosclerosis, cardiovascular risk | Overexpression in macrophages, KO mice |
| PAFAH1B2 | Inflammation, PAF metabolism | Point mutation in catalytic site, KO cell lines |
| PAFAH1B3 | Inflammation, PAF metabolism | Knockdown in endothelial cells |
| DYNC1H1 | Neurodevelopmental disorders | Knock-in of patient mutations in neurons |
Lissencephaly and Neurodevelopmental Disorders
Mutations in PAFAH1B1 (LIS1), the gene encoding the beta subunit of the PAF-AH complex, cause lissencephaly, a severe brain malformation characterized by a smooth cerebral cortex and intellectual disability. LIS1 is critical for neuronal migration, and its loss leads to impaired dynein function and disrupted cortical development. The PAF-AH complex's role in lipid metabolism may also contribute to the pathology, as PAF signaling can affect neuronal survival and inflammation.
Cardiovascular Diseases
The secreted form of PAF-AH, Lp-PLA2 (encoded by PLA2G7), is a well-established biomarker for cardiovascular risk. Elevated Lp-PLA2 activity is associated with atherosclerosis, stroke, and coronary heart disease. Although the intracellular complex (GO:0008247) is distinct, it also contributes to PAF degradation and may influence vascular inflammation. Inhibitors of PAF-AH have been explored as therapeutic agents, but clinical trials have yielded mixed results.
Inflammation and Sepsis
PAF is a potent mediator of inflammation and septic shock, and the PAF-AH complex plays a key role in terminating PAF signaling. Reduced PAF-AH activity has been observed in sepsis and other inflammatory conditions, suggesting that the complex is important for resolving inflammation. Modulating the complex's activity could be a therapeutic strategy for inflammatory diseases.
From 1-alkyl-2-acetylglycerophosphocholine esterase complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of PAFAH1B1 knockout on neuronal migration? | Knockout of PAFAH1B1 in mouse embryonic brain or human iPSC-derived neurons |
| How does a point mutation in the catalytic serine of PAFAH1B2 affect PAF-AH activity? | Point mutation (S->A) knock-in in cell lines, followed by enzyme assay |
| Where is the PAF-AH complex localized in cells? | Tagged knock-in of PAFAH1B1 with GFP for live imaging |
| What is the effect of PAFAH1B1 overexpression on dynein function? | Overexpression of PAFAH1B1 in cultured neurons |
| How does the beta subunit regulate complex assembly? | Knockout of PAFAH1B1 and rescue with wild-type or mutant beta subunit |
| What are the interactors of the PAF-AH complex? | Affinity purification with tagged beta subunit followed by mass spectrometry |
How to Study the 1-alkyl-2-acetylglycerophosphocholine esterase complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| PAF-AH activity assay | Enzymatic hydrolysis of PAF | Kinetic analysis of wild-type and mutant complexes |
| Co-immunoprecipitation | Protein-protein interactions | Identifying subunits and partners |
| Mass spectrometry | Protein identification and modifications | Mapping interactome and post-translational modifications |
| Fluorescence microscopy | Subcellular localization | Tracking tagged subunits in live cells |
| CRISPR knockout | Gene function | Studying loss-of-function phenotypes |
| RNA-seq | Transcriptional changes | Assessing downstream effects of complex disruption |
| Proteomics | Global protein expression | Uncovering pathways affected by PAF-AH complex |
| Organoid culture | 3D tissue-like structures | Modeling neurodevelopmental disorders |
Enzymatic Activity Assays
PAF-AH activity is typically measured using radiolabeled or fluorescent PAF analogs. The hydrolysis of PAF to lyso-PAF can be quantified by thin-layer chromatography or mass spectrometry. These assays are essential for determining the kinetic parameters of the complex and the effects of mutations.
Protein-Protein Interaction Studies
Co-immunoprecipitation and affinity purification coupled with mass spectrometry can identify subunits and interacting partners of the PAF-AH complex. For example, tagging the beta subunit (LIS1) has revealed its interaction with dynein and other proteins. These methods help elucidate the complex's assembly and regulation.
Imaging and Localization
Fluorescence microscopy of tagged subunits (e.g., GFP-LIS1) allows visualization of the complex's subcellular localization in live cells. This is particularly important for understanding its role in neuronal migration and dynein-mediated transport.
Genetic and CRISPR Screens
CRISPR knockout screens can identify genes that modulate PAF-AH complex function or PAF signaling. For instance, knocking out PAFAH1B1 in cell lines followed by phenotypic analysis can reveal its role in proliferation or migration. Such screens are powerful for uncovering novel regulators.
How CRISPR Can Be Used to Study GO:0008247 1-alkyl-2-acetylglycerophosphocholine esterase complex
Knockout
CRISPR knockout of PAFAH1B1, PAFAH1B2, or PAFAH1B3 can abolish PAF-AH complex activity, leading to increased PAF levels and altered cellular responses. Knockout cell lines are valuable for studying the complex's role in inflammation, neuronal migration, and dynein function. For example, PAFAH1B1 knockout in human iPSC-derived neurons recapitulates lissencephaly phenotypes.
Point Mutation
Introducing point mutations in the catalytic triad of the alpha subunits (e.g., serine to alanine) can generate catalytically dead complexes, allowing researchers to separate catalytic activity from structural functions. Similarly, patient-derived mutations in PAFAH1B1 can be knocked in to study lissencephaly mechanisms.
Knock-in
Knock-in of tagged versions of the subunits (e.g., GFP or HA tags) enables visualization and affinity purification of the complex. This approach is useful for tracking the complex's localization and interactions in real time. Knock-in of disease-associated mutations can also model human disorders.
Overexpression
Overexpression of the beta subunit or alpha subunits can lead to increased complex formation and altered PAF metabolism. This is useful for gain-of-function studies, such as investigating the effect of LIS1 overexpression on dynein-mediated transport. Overexpression models can also help identify dose-dependent effects.
How EDITGENE Supports 1-alkyl-2-acetylglycerophosphocholine esterase complex Research
Researchers studying 1-alkyl-2-acetylglycerophosphocholine esterase complex-related genes often need to determine whether a candidate gene is causally involved in PAF metabolism, neuronal migration, or inflammation. Generating precise genetic models is essential to dissect the contributions of each subunit and their disease-associated mutations.
Contact EDITGENE today to design your custom CRISPR model for 1-alkyl-2-acetylglycerophosphocholine esterase complex research.
Frequently Asked Questions About 1-alkyl-2-acetylglycerophosphocholine esterase complex
What is the 1-alkyl-2-acetylglycerophosphocholine esterase complex?
It is an enzyme complex, also known as PAF acetylhydrolase, that degrades platelet-activating factor (PAF) by removing its acetyl group.
What genes are involved in the 1-alkyl-2-acetylglycerophosphocholine esterase complex?
The complex is encoded by PAFAH1B1 (beta subunit), PAFAH1B2 (alpha2), and PAFAH1B3 (alpha1).
What is the function of GO:0008247?
GO:0008247 represents the cellular component term for the PAF-AH complex, which modulates PAF action through hydrolysis.
How is the PAF-AH complex structured?
It is a heterotrimer of two catalytic alpha subunits (alpha1/alpha1, alpha2/alpha2, or alpha1/alpha2) and one regulatory beta subunit.
What diseases are associated with the PAF-AH complex?
Mutations in PAFAH1B1 cause lissencephaly, and altered PAF-AH activity is linked to cardiovascular and inflammatory diseases.
What is the role of LIS1 in the PAF-AH complex?
LIS1 is the beta subunit; it regulates the complex and also functions in dynein-mediated neuronal migration.
How can I study the PAF-AH complex in the lab?
Common methods include enzymatic assays, co-immunoprecipitation, fluorescence microscopy, and CRISPR knockout models.
What CRISPR models are available for PAF-AH research?
Knockout, point mutation, knock-in, and overexpression models can be generated for PAFAH1B1, PAFAH1B2, and PAFAH1B3.
Is the PAF-AH complex involved in cancer?
PAF signaling has been implicated in tumor progression, and the complex may influence cancer-related inflammation.
Where is the PAF-AH complex localized in cells?
It is primarily cytosolic but can associate with membranes and the cytoskeleton, especially via the beta subunit's interaction with dynein.
Conclusion
The 1-alkyl-2-acetylglycerophosphocholine esterase complex (GO:0008247) is a critical regulator of platelet-activating factor signaling, with essential roles in inflammation, vascular biology, and neurodevelopment. Its unique heterotrimeric structure, comprising two catalytic alpha subunits and a regulatory beta subunit (LIS1), links lipid metabolism to dynein-mediated transport and neuronal migration. Mutations in the beta subunit cause lissencephaly, underscoring its clinical importance. Advances in CRISPR-based models and screening technologies are enabling deeper exploration of this complex, promising new insights into its function and therapeutic potential.
References
- 1. Singh K et al.. 2024. Molecular mechanism of dynein-dynactin complex assembly by LIS1.. Science 383(6690):eadk8544 PMID: 38547289
- 2. So C et al.. 2022. Mechanism of spindle pole organization and instability in human oocytes.. Science 375(6581):eabj3944 PMID: 35143306
- 3. Derewenda ZS et al.. 1999. PAF-acetylhydrolases.. Biochim Biophys Acta 1441(2-3):229-36 PMID: 10570251
- 4. Lambert de Rouvroit C et al.. 2001. Neuronal migration.. Mech Dev 105(1-2):47-56 PMID: 11429281
- 5. Zillich L et al.. 2025. Capturing disease severity in LIS1-lissencephaly reveals proteostasis dysregulation in patient-derived forebrain organoids.. Nat Commun 16(1):9091 PMID: 41083500
- 6. Garcia-Garcia HM et al.. 2009. Phospholipase A2 inhibitors.. Curr Opin Lipidol 20(4):327-32 PMID: 19550325
- 7. Rao Q et al.. 2026. Roles of microtubules and LIS1 in dynein transport machinery assembly.. Nature 652(8112):1384-1392 PMID: 41708859
- 8. Wimmer R et al.. 2026. Two translocation mechanisms drive neural stem cell dissemination into the human fetal cortex.. Neuron 114(12):2165-2182.e6 PMID: 41844158
